



HORMONAL THERAPIES

E-SCRIBE and FAX ENROLLMENT FORM

NOBLE NORTHEAST: E-Scribe: NOBLE | Fax: 888-842-3977 | Tel: 888-843-2040

NOBLE SOUTHEAST: E-Scribe: NOBLEMS/TRANSCRIPT | Fax: 601-420-4040 | Tel: 866-420-4041

Delivery Needed By: _____ Deliver to: Patient's Home Physician's Office Other: _____

PATIENT INFORMATION	PROVIDER INFORMATION
Patient Name: _____ <input type="checkbox"/> Male	Prescriber's Name: _____
Street Address: _____ <input type="checkbox"/> Female	Office Contact Name: _____
City: _____ State: _____ Zip Code: _____	Address: _____
Phone Number: _____	City: _____ State: _____ Zip Code: _____
Email Address: _____	Phone Number: _____
Last Four of Social: _____ Date of Birth: _____	Fax Number: _____
Translator Needed: <input type="checkbox"/> Yes <input type="checkbox"/> No Language: _____	DEA/NPI #: _____

INSURANCE - PLEASE FAX A COPY OF PRESCRIPTION CARD FRONT & BACK

CLINICAL INFORMATION	
Diagnosis: _____	Has the patient been treated previously for this condition? <input type="checkbox"/> Yes <input type="checkbox"/> No
ICD-10 Code: _____	
Height: _____ ft _____ ins Weight: _____ lbs	Medications Failed: _____
Allergies: _____	Medications On: _____
Other Notes: _____	

PRESCRIPTION INFORMATION				
Medication:	Dosage/Strength:	Directions:	Quantity:	Refills:
Firmagon®	<input type="checkbox"/> 120mg vial <input type="checkbox"/> 80mg vial	<u>Initial Dose:</u> <input type="checkbox"/> Inject 240mg (2-120mg injections) SC <u>Maintenance Dose:</u> <input type="checkbox"/> Inject 80mg SC every 28 days	<input type="checkbox"/> 4-week supply	
Lupaneta Pack™ leuprolide, norethindrone	<input type="checkbox"/> 3.75mg suspension for injection, 5mg tablet <input type="checkbox"/> 11.25mg suspension for injection, 5mg tablet	<input type="checkbox"/> 3.75mg IM once monthly, 5mg tablet by mouth once daily <input type="checkbox"/> 11.25mg IM once every 3 months, 5mg tablet by mouth once daily	<input type="checkbox"/> 1 pack	
Lupron Depot®	<input type="checkbox"/> 3.75mg suspension for injection <input type="checkbox"/> 7.5mg suspension for injection <input type="checkbox"/> 11.25mg suspension for injection <input type="checkbox"/> 22.5mg suspension for injection <input type="checkbox"/> 30mg suspension for injection <input type="checkbox"/> 45mg suspension for injection	<input type="checkbox"/> _____mg IM once monthly <input type="checkbox"/> _____mg IM once every 3 months <input type="checkbox"/> _____mg once every 4 months <input type="checkbox"/> _____mg once every 6 months	<input type="checkbox"/> 1 dose	
Supprelin® LA	<input type="checkbox"/> 50mg subcutaneous implant	<input type="checkbox"/> 1 implant inserted subcutaneously every 12 months	<input type="checkbox"/> 1 implant	
Trelstar®	<input type="checkbox"/> 3.75mg suspension for injection <input type="checkbox"/> 11.25mg suspension for injection <input type="checkbox"/> 22.5mg suspension for injection	<input type="checkbox"/> _____mg IM once monthly <input type="checkbox"/> _____mg IM once every 3 months <input type="checkbox"/> _____mg once every 6 months	<input type="checkbox"/> 1 dose	
Vantas™	<input type="checkbox"/> 50mg subcutaneous implant	<input type="checkbox"/> 1 implant inserted subcutaneously every 12 months	<input type="checkbox"/> 1 implant	
Zoladex®	<input type="checkbox"/> 3.6mg implant <input type="checkbox"/> 10.8mg implant	<input type="checkbox"/> 3.6 mg subcutaneous into the upper abdominal wall every 28 days <input type="checkbox"/> 10.8 mg subcutaneous into the upper abdominal wall once every 12 weeks <input type="checkbox"/> Other	<input type="checkbox"/> 1 dose	
Other				

Patient is interested in patient support programs
 Ancillary supplies provided for administration

Physician Signature: _____

Date: _____

NATIONALLY ACCREDITED. 100% EMPLOYEE OWNED.
www.noblehealthservices.com

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. V.Q420201